Fig. 2.

Co-treatment with 400μg IFN subtype DNA does not affect acute-phase MCMV infection or myocarditis. Bupivacaine treated BALB/c mice were inoculated with Blank vector or combinations of IFNA6/Blank, IFNA9/Blank, IFNB/Blank, IFNA6/A9, IFNA6/B, and IFNA9/B DNA at a dosage of 200μg per transgene to a total of 400μg DNA, bilaterally via the TA muscle. At 14 days post-inoculation, mice were challenged with 1x104 pfu MCMV i.p. Viral titres were determined in (A) spleen and (B) liver at day 3 p.i. and (C) salivary glands at day 7 p.i. and are expressed as pfu/g tissue ± SEM (n=5). (D) Myocarditis was evaluated at day 7 p.i. and is expressed as the number of foci per heart section ± SEM (n=5). *, Statistical significance (p≤0.05) compared with Blank treatment groups. Bl. denotes Blank expression vector.